Articles

Boston Scientific, fully absorbable scaffold, FAST study, resorbable

Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study (FAST) is a prospective, single-arm...

electronic stents, bioresorbable electronic stent, BES

With the recent innovation of flexible microelectronic sensor circuits that can be made from bioresorbable materials, it is now possible to create “electronic stents” to monitor a treated lesion...

ART, PBS, pure bioresorbable scaffold, CE Mark

Privately-held company Arterial Remodeling Technologies (ART) announced CE Mark clearance for its next-generation drug-free, pure bioresorbable scaffold used to treat coronary artery disease. The...

bioresorbable stents

Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely expected to overtake metallic stents in the coming years if the data trend...

October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is more cost effective and offers a...

ABSORB II Study DES Xience Abbot Vascular

Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb...

bioresorbable stents, dissolving stents, Absorb stent, BVS

A key prediction for interventional cardiology coming out of recent Transcatheter Cardiovascular Therapeutics (TCT) and American College of Cardiology (ACC) meetings is that bioresorbable stents...

Elixir Medical Corp. DESolve 100 CE mark

Elixir Medical Corp. received CE mark approval for its DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System.

April 16, 2014 — Abbott announced it has completed enrollment of three clinical trials to support approvals of the company's Absorb bioresorbable vascular scaffold (BVS) in the United States,...

Terumo Corp. Arterial Remodeling Technologies Bioresorbable Coronary Stent

Privately held Arterial Remodeling Technologies (ART) signed a structured buyout agreement with Terumo Corp. Under the agreement, ART and Terumo Corp. will collaborate in the development of a drug...